Related Experiment Video
Updated: May 6, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Prophylactic systemic P2X7 receptor blockade prevents experimental colitis
Carla Caldas Marques1, Morgana T Castelo-Branco, Rodrigo G Pacheco
1Departamento de Clínica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil; Laboratório de Imunologia Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil.
Background:
The P2X7 receptor (P2X7-R) is a non-selective adenosine triphosphate-gated cation channel present in epithelial and immune cells, and involved in inflammatory response. Extracellular nucleotides released in conditions of cell stress or inflammation may function as a danger signal alerting the immune system from inflammation. We investigated the therapeutic action of P2X7-R blockade in a model of inflammatory bowel disease.
Methods:
Rats with trinitrobenzene sulfonic (TNBS) acid-induced colitis were treated with the P2X7-R antagonists A740003 or brilliant blue G (BBG) through intra-peritoneal (IP) or intra-colonic (IC) injection prior to colitis induction. Clinical and endoscopic follow-up, histological scores, myeloperoxidase activity, densities of collagen fibers and goblet cells were evaluated. P2X7-R expression, NF-kappa B and Erk activities, and densities of T-cells and macrophages were analyzed by immunoperoxidase. The inflammatory response was determined by measuring inflammatory cytokines in cultures of colon explants, by enzyme-linked immunosorbent assay. Colonic apoptosis was determined by the TUNEL assay.
Results:
IP-BBG significantly attenuated the severity of colitis, myeloperoxidase activity, collagen deposition, densities of lamina propria T-cells and macrophages, while maintaining goblet cell densities. IP-BBG inhibited the increase in P2X7-R expression in parallel with apoptotic rates. TNF-α and interleukin-1β stabilized in low levels, while TGF-β and interleukin-10 did not change following IP-BBG-therapy. Colonic NF-kappa-B and Erk activation were significantly lower in IP-BBG-treated animals. Prophylactic IP-A740003 also protected rats against the development of TNBS-colitis.
Conclusions:
Prophylactic systemic P2X7-R blockade is effective in the prevention of experimental colitis, probably due to a systemic anti-inflammatory action, interfering with a stress-inflammation amplification loop mediated by P2X7-R.
Insights
Systemic blockade of the P2X7 receptor (P2X7-R) effectively prevents experimental colitis by reducing inflammation. This therapeutic strategy targets a key pathway amplifying stress and inflammation in the gut.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- The P2X7 receptor (P2X7-R) is a cation channel on immune and epithelial cells, crucial for inflammatory responses.
- Extracellular nucleotides act as danger signals, activating P2X7-R and initiating inflammation.
Purpose of the Study:
- To investigate the therapeutic potential of P2X7-R blockade in a rat model of inflammatory bowel disease (IBD).
Main Methods:
- Rats with TNBS-induced colitis were treated with P2X7-R antagonists (A740003, BBG) via IP or IC injection.
- Evaluated clinical, endoscopic, histological, and molecular markers of inflammation, including cytokine levels and immune cell infiltration.
Main Results:
- Systemic BBG treatment significantly reduced colitis severity, myeloperoxidase activity, and collagen deposition.
- BBG inhibited P2X7-R expression, NF-kappa B and Erk activation, and inflammatory cytokine levels (TNF-α, IL-1β).
- Prophylactic A740003 also demonstrated protective effects against TNBS-colitis.
Conclusions:
- Systemic P2X7-R blockade shows efficacy in preventing experimental colitis.
- The mechanism involves a systemic anti-inflammatory action, disrupting a stress-inflammation amplification loop mediated by P2X7-R.
More Related Videos
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

